Practical Biotechnology
Triple Negative Breast Cancer (TNBC) is associated with higher metastatic potential, more rapid disease progression and worse outcomes than any other breast cancer. It accounts for up to 15% of all breast cancers and patients with TNBC have a 30% recurrence rate. Metastatic forms have 5 year survival rates as low as 11%. TNBC is particularly deadly in young women, BRCA1/2 families and African American women.
Our mission is to use the PARTHEX series of compounds as single and combinatorial therapies for triple negative breast cancer and other aggressive human malignancies.
“every two minutes a woman is diagnosed with invasive breast cancer”
— Susan G. Komen Foundation